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Introduction: Galectin-9 ameliorates various inflammatory conditions including autoimmune diseases by regulating
T cell and macrophage/dendritic cell (DC) functions. However, the effect of galectin-9 on polymicrobial sepsis has
not been assessed.
Methods: We induced polymicrobial sepsis by cecal ligation and puncture (CLP) in mice. The survival rate was
compared between galectin-9- and PBS-treated CLP mice. An ELISA was used to compare the levels of various
cytokines in the plasma and culture supernatants. Fluorescence-activated cell sorting analysis was further performed
to compare the frequencies of subpopulations of spleen cells.
Results: Galectin-9 exhibited a protective effect in polymicrobial sepsis as demonstrated in galetin-9 transgenic
mice and therapeutic galectin-9 administration. In contrast, such effect was not observed in nude mice, indicating
the involvement of T cells in galectin-9-mediated survival prolongation. Galectin-9 decreased TNFα, IL-6, IL-10 and,
high mobility group box 1 (HMGB1) and increased IL-15 and IL-17 plasma and spleen levels. Galectin-9 increased
the frequencies of natural killer T (NKT) cells and PDCA-1+ CD11c+ macrophages (pDC-like macrophages) but did
not change the frequency of CD4 or CD8 T cells, γδT cells or conventional DC. As expected, galectin-9 decreased
the frequency of Tim-3+ CD4 T cells, most likely Th1 and Th17 cells. Intriguingly, many spleen NK1.1+ NKT cells
and pDC-like macrophages expressed Tim-3. Galectin-9 increased the frequency of Tim-3-expressing NK1.1+ NKT
cells and pDC-like macrophages. Galectin-9 further increased IL-17+ NK1.1+ NKT cells.
Conclusion: These data suggest that galectin-9 exerts therapeutic effects on polymicrobial sepsis, possibly
by expanding NKT cells and pDC-like macrophages and by modulating the production of early and late
proinflammatory cytokines.Introduction
Sepsis is the leading cause of death in critically ill patients,
and the incidence of sepsis is increasing. The mortality
rate of severe sepsis is very high, up to 70%. Two types of
animal sepsis model have been established: the lipo-
polysaccharide(LPS)-induced inflammation, and the cecal
ligation and puncture (CLP) model of microbial sepsis.* Correspondence: mitsuomi@kms.a
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reproduction in any medium, provided the orLPS stimulates macrophages to release large amounts of
TNFα and IL-1β that can precipitate tissue injury and
lethal shock. Antagonists of TNFα and IL-1β have shown
limited efficacy in clinical trials, most likely because these
cytokines are early mediators in sepsis pathogenesis [1,2].
On the other hand, high mobility group box 1 (HMGB1)
is thought to be a late mediator of endotoxin lethality in
mice, and HMGB1 is first detectable in the circulation 8
hours after the onset of sepsis disease, subsequently
increasing to plateau levels from 16 to 32 hours [3]. Ad-
ministration of HMGB1-specific neutralizing antibodies
beginning 24 hours after the onset of sepsis induced by
CLP was shown to lead to a dose-dependent rescue of
mice from lethal sepsis [4-6].ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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death-1 (PD-1) expression on macrophages is critically
associated with altering microbial clearance and the
innate inflammatory response to sepsis in CLP mice [7].
Upregulation of PD-1 on T cells and the PD-ligand (L) 1
on monocytes in patients with septic shock has also
been observed [8], and it has been shown that PD-1
levels correlate with increased mortality, nosocomial in-
fections, and immune dysfunction in patients with septic
shock [9]. Moreover, blockade of the PD-1/PD-L1 path-
way improves survival in CLP mice by reversing immune
dysfunction [10-12].
Galectin-9 (Gal-9) is a member of the galectin family
that selectively binds to β-galactoside [13]. Gal-9 was
first identified as an apoptosis-inducing factor for
thymocytes [14] and an eosinophil-activating factor [15].
However, recent experiments have revealed that Gal-9 is
a ligand of Tim-3 that is expressed on Th1 and Th17
cells, and that Gal-9 signaling induces death of these
cells, resulting in the suppression of Th1- and Th17-
related cytokine production in vivo and in vitro [16,17].
More recently, it has been shown that Gal-9 derived
from surface Gal-9-expressing Th cells (ThGal-9)
suppresses the development of Th17 cells and enhances
the development of FoxP3+ regulatory T cells (Tregs) in
a Tim-3-independent manner [18]. In addition to the
above mechanisms, Gal-9 modulates immune responses
by expanding myeloid suppressor cells [19] and plasma-
cytoid dendritic cell (pDC)-like macrophages [20-23].
We have also shown that Gal-9 ameliorates LPS-induced
inflammation and protects mice from an LPS-induced
Schwartzman reaction by suppressing the production of
proinflammatory cytokines from LPS-stimulated macro-
phages and activating PGE2-producing neutrophils,
respectively [24]. Therefore, it is of interest to examine
the role of Gal-9 in a murine model of polymicrobial
sepsis induced by CLP. The purpose of the present
experiment is to show a beneficial effect of Gal-9 in a
murine sepsis model induced by CLP and to clarify
possible functions of Gal-9 in this model.
Materials and methods
Mice
Female wild-type (WT) Balb/c mice and Gal-9 trans-
genic (TG) mice were used in the present study [24].
These mice were maintained on a 12:12-hour light–
dark cycle under specific pathogen-free conditions at
Kagawa University. The animals were fed a standard
laboratory diet and were provided water ad libitum.
All experimental procedures were approved by the
Animal Care and Use Committee of Kagawa University.
The animals used in this research received humane
care in accordance with international guidelines and
national law.Induction of sepsis
CLP appears to be a reliable and clinically relevant
animal model of the human septic condition because it
produces an endogenous polymicrobial infection similar
to clinical peritonitis and sepsis. Thus, sepsis was in-
duced by CLP in the present experiments as described
elsewhere [25]. Briefly, mice were anesthetized, and the
cecum was exposed, ligated with a 3–0 silk suture and
punctured once with an 18-gauge needle. The cecum
was then replaced in the peritoneal cavity, and the inci-
sion was closed with surgical staples. All mice received a
subcutaneous injection of 1 ml of sterile saline to avoid
dehydration and were placed on a heating pad until they
recovered from anesthesia. All mice were allowed free
access to food and water throughout the experiments.
We used stable human Gal-9 [26] to assess the effects of
Gal-9 on the survival of CLP mice. The purity of Gal-9
was >95%. The endotoxin level was determined using a
Limulus assay (BioWhittaker, Tokyo, Japan) and was
found to be <0.008 endotoxin units. CLP mice were
treated with Gal-9 intravenously or subcutaneously im-
mediately after CLP unless otherwise specified. To deter-
mine the survival of the mice, CLP mice were monitored
for 7 days after CLP. In a different set of experiments,
CLP mice were anesthetized, bled and euthanized at
indicated time points after CLP.
Bacterial colony-forming unit determination
The peritoneal cavities were washed with 2 ml of sterile
saline, and the lavage fluids were harvested. A 10 μl
aliquot of lavage fluids was used to assess bacterial
colony-forming units (CFU). Peritoneal fluids (PF, 10 μl)
from each mouse were serially diluted with sterile saline.
Each PF dilution was plated on tryptic soy blood agar
plates and incubated overnight at 37°C, after which the
number of aerobic colonies was counted. Data were
expressed as CFU per 10 μl PF.
Cell preparation
Spleens were obtained at 24 hours after CLP from mice
treated with PBS or Gal-9 immediately after CLP and
dispersed into single-cell suspensions. Red blood cells
(RBC) were lysed with 0.1 N NH4Cl, and the spleen cells
were washed three times with Roswell Park Memorial
Institute medium (RPMI) 1640 and cultured in RPMI
1640 solution supplemented with 5% FCS, glutamine
and antibiotics in a 5% CO2 incubator for 48 hours.
Measurement of cytokines
Murine cytokines were quantitated using a standard
sandwich ELISA according to the manufacturer’s pro-
tocol. The capture antibodies (Abs), detection Abs
and the recombinant cytokines were purchased from
R&D Systems or BioLegend. The ELISAs used in this
Figure 1 Survival of galectin (Gal)-9 transgenic (TG) mice
during polymicrobial sepsis induced by cecal ligation and
puncture (CLP). (A) Prolonged survival of Gal-9 TG mice. CLP was
performed, and survival was monitored for 7 days after CLP in
wild-type (WT) and Gal-9 TG CLP mice. The log-rank (Mantel-Cox)
test was used for statistical analysis; P <0.01. (B) Cytokine levels in
peritoneal fluids (PF) from WT (n = 18) and Gal-9 TG (n = 19) mice.
At 24 hours after CLP, PF was obtained and ELISA was used for
quantification of cytokine levels (*P <0.05; NS, not significant). (C)
Bacterial load in WT (n = 11) and Gal-9 TG (n = 8) mice. PF dilutions
were plated on tryptic soy blood agar plates and incubated
overnight at 37°C. The number of aerobic colonies was counted.
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cytokines.
Flow cytometry analysis
Spleen cells were harvested from WT and Gal-9 TG
CLP mice at 24 hours after CLP, and the cells (1 × 106
cells/ml) were suspended in PBS supplemented with 2%
FCS and 0.1% sodium azide. Cells were stained with
mAbs specific for mouse CD3, CD4, CD8, GL-3, NK1.1
and Tim-3 (BioLegend, Tokyo, Japan). Stained cells were
analyzed using a FACSCalibur (BD Biosciences, Tokyo,
Japan). To assess intracellular IL-17 production, spleen
cells were cultured for 48 hours in the presence of 1 μg/ml
brefeldin A (Sigma, Tokyo, Japan) and were permeabilized
overnight with permeabilization buffer (Cytofix/Cytoperm;
eBioscience, San Diego, CA, USA).
Statistics
Statistical significance was determined using the Mann–
Whitney U-test. In the case of survival curves, the data
were analyzed using the log-rank test. A P-value <0.05
was regarded as statistically significant. All data were
expressed as mean ± standard error of the mean (SEM).
Results and discussion
Improved survival in CLP-induced sepsis in Gal-9 TG mice
We first compared the survival rate after CLP between
(WT and Gal-9 TG mice. The survival rate of Gal-9 TG
mice was significantly higher than that of WT mice. Of
the 19 Gal-9 TG mice, 12 survived to day 7 after CLP
(63.2%), whereas only 3 of 18 WT mice survived to day
7 (16.7%) (P <0.01). Thus, Gal-9 TG mice were resistant
to the lethality induced by CLP, thereby suggesting a
beneficial effect of Gal-9 administration in mice under-
going CLP (Figure 1A).
To uncover the mechanism by which Gal-9 prolongs
the survival of CLP mice, we assessed the levels of pro-
inflammatory cytokines such as TNF-α and IL-1β in the
PF of WT and Gal-9 TG mice at 24 hours after CLP.
Figure 1B shows that the levels of TNF-α and IL-1β
were relatively decreased at this time point and that the
level of IL-12 was relatively increased in Gal-9 TG mice
compared to WT mice. However, we previously showed
that the levels of TNF-α and IL-12 in PF were signifi-
cantly suppressed in Gal-9 TG mice during early periods
(1 to 6 hours) of LPS-induced peritoneal inflammation
[24]. In contrast, the levels of IFNγ and IL-10 were
significantly decreased in Gal-9 TG mice.
We further tested whether Gal-9 could decrease the
bacterial load in PF at 24 hours after CLP. The bacterial
load in Gal-9 TG mice tended to be lower than the
bacterial load in WT mice but the difference was not
statistically significant (Figure 1C). No bacterial CFU or
few bacterial CFU were found at 7 days after CLP inthe PF of Gal-9-treated surviving mice, as expected
(data not shown).
Delayed Gal-9 treatment prolongs the survival of CLP mice
To determine whether Gal-9 exhibits protective effects
in CLP mice, we treated CLP mice with a single Gal-9
administration (intravenous (i.v.), 30 μg/mouse) immedi-
ately after CLP. As shown in Figure 2A, 7 of 16 Gal-9-
treated CLP mice survived at day 7 after CLP (43.8%),
whereas only 2 of 16 PBS-treated mice survived at this
time point (12.5%) (P <0.05). We further failed to detect
any significant difference in the bacterial loads of the PF
between PBS- and Gal-9-treated mice at 24 hours after
CLP (Figure 2B). Similar to Gal-9 TG mice, no bacterial
Figure 2 Delayed galectin (Gal)-9 treatment prolongs the survival of cecal ligation and puncture (CLP) mice. (A) CLP mice received a
single Gal-9 injection (intravenous (i.v.), 30 μg/mouse) immediately after CLP, and survival was monitored for 7 days. The log-rank (Mantel-Cox)
test was used for statistical analysis. (B) Bacterial load in peritoneal fluid (PF) in PBS- (n = 14) and Gal-9-treated (n = 13) mice at 24 hours after CLP.
PF dilutions were plated on tryptic soy blood agar plates and incubated overnight at 37°C. The number of aerobic colonies was counted (NS, not
significant). (C) Therapeutic effects of delayed i.v. Gal-9 injection on septic mice induced by CLP. Gal-9 was injected i.v. at 24 hours after CLP, and
survival was monitored for 7 days. The log-rank (Mantel-Cox) test was used for statistical analysis; P <0.05. (D) No therapeutic effects of i.v. Gal-9
injected immediately after CLP in nude mice. The log-rank (Mantel-Cox) test was used for statistical analysis of survival.
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CLP in the PF of Gal-9-treated surviving mice (data not
shown). These results suggest that direct bacterial
suppression by Gal-9 is not the trigger for this prolonged
survival. Further studies are required to ascertain the
mechanisms how Gal-9 finally decreases bacterial CFU
on Day 7.
Furthermore, delayed i.v. Gal-9 administration given at
24 hours after CLP also significantly prolonged the sur-
vival of CLP mice: 11 of 15 Gal-9-treated mice survived
at day 7 after CLP (73.3%), whereas only 4 of 16 PBS-
treated mice survived at this time point (25%) (P <0.05)
(Figure 2C). Moreover, we found that delayed sub-
cutaneous Gal-9 treatment given at 24 hours after CLP
similarly prolonged the survival of CLP mice: 15 of 22
Gal-9-treated mice survived at day 7 after CLP (68.2%),
whereas 8 of 22 PBS-treated mice survived at this time
point (40.0%) (P = 0.058). These results suggest that
Gal-9 has therapeutic effects on microbial sepsis, prob-
ably by modulating the immune response to prolong the
survival of CLP mice.
Interestingly, Gal-9 did not exhibit any therapeutic
effects in nude mice: All animals that received Gal-9
administration died by 3 days after CLP similar to CLP
mice that did not receive Gal-9 (Figure 2D), suggestingthat T cells are critically involved in the survival
enhancement mediated by Gal-9.
Effects of Gal-9 on plasma levels of cytokines
To determine the functions of Gal-9 in CLP mice,
plasma levels of pro-inflammatory cytokines were
assessed. Similar to the Gal-9 TG mice, Gal-9 failed
to affect the levels of early pro-inflammatory cyto-
kines such as TNF-α at 24 hours after CLP, although
the level of IL-6 was suppressed by Gal-9 (Figure 3).
In contrast, the level of HMGB1, a late inflammatory
mediator [3], was markedly suppressed in Gal-9-treated
mice at 24 hours after CLP (Figure 3). This result seems
reasonable because delayed administration of anti-
bodies against HMGB1 attenuates endotoxin lethality
[3] and CLP-induced sepsis in rodents [4,5]. Fur-
thermore, we found a decreased level of IL-10 and
increased levels of IL-15 and IL-17 in Gal-9-treated
CLP mice.
Based on the above results, we hypothesized that
Gal-9 plays a critical role in not only the early but
also in the late stage of sepsis, in which HMGB1
plays a critical role [27] to protect mice from lethal-
ity. This conclusion is based on our previous findings
that Gal-9 administration suppresses the production
Figure 3 Effects of galectin (Gal)-9 on plasma cytokine levels in cecal ligation and puncture (CLP) mice. Plasma was prepared at 24 h after
a single intravenous (i.v.) Gal-9 injection (i.v., 30 μg/mouse) immediately after CLP, and plasma cytokines were assessed by ELISA analysis; n = 8 to
12; NS, not significant; *P <0.05; **P <0.01; ***P <0.001). HMGB1, high mobility group box 1.
Kadowaki et al. Critical Care 2013, 17:R284 Page 5 of 11
http://ccforum.com/content/17/6/R284of pro-inflammatory cytokines (TNF-α, IL-12 and IFNγ)
during early time points (1 to 6 hours) following
LPS-induced inflammation [24].
Effects of Gal-9 on cytokine production from spleen cells
The next set of experiments was performed to compare
the levels of cytokine production from spleen cells from
PBS- and Gal-9-treated CLP mice. Spleen cells were
obtained at 24 hours after CLP and cultured without any
stimulation for 48 hours. Spleen cells from Gal-9-treated
CLP mice released decreased levels of early and late
proinflammatory cytokines such as TNFα, IL-6, IL-12
and HMGB1 (Figure 4). The level of IL-10 was also de-
creased in Gal-9-treated CLP mice (Figure 4). Although
IL-10 is an immunosuppressive cytokine, neutralization
of IL-10 leads to improved survival of septic mice by
restoring the downregulation of the IL-18 receptor on
NK cells and IFN-γ production [28,29].In contrast, an increase in IL-17 production was
observed from spleen cells from Gal-9-treated CLP mice
(Figure 4), which is unexpected because Gal-9 reduces
IL-17-producing Th17 cells by inducing apoptosis and
downregulating the differentiation of Th17 cells [17,18].
IL-17 is a proinflammatory cytokine produced during
acute, delayed and autoimmune inflammation [30]. In
addition to Th17 cells, other T cells such as CD8 T cells
(Tc17) [31,32], natural killer T (NKT) cells [33,34] and
γδT cells [35,36] could be the source of IL-17. In
autoimmune diseases, it is important to reduce pro-
inflammatory IL-17 levels to improve disease severity
[17]. In contrast, IL-17 plays a critical role in protecting
mice from sepsis-mediated lethality [37,38].
Furthermore, Gal-9 treatment resulted in an increase
in IL-15 production compared to PBS-treated mice
(Figure 4). IL-15 is an anti-apoptotic cytokine that
prevents apoptosis by inducing apoptosis inhibitors
Figure 4 Effects of galectin (Gal)-9 on cytokine production from spleen cells. Spleen cells were obtained at 24 hours after cecal ligation and
puncture and PBS or Gal-9 injection. These cells were then cultured without any stimulation for 48 hours, and an ELISA assay was used for
quantification of cytokine levels released by the spleen cells; n = 6 to 8; NS, not significant; *P <0.05; ***P <0.001.
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that IL-15 prevents apoptosis, reverses innate and
adaptive immune dysfunction and improves survival
in a sepsis model. Therefore, it seems reasonable that
there is upregulation of IL-17 and IL-15 in Gal-9-
treated CLP mice that are resistant to CLP-induced
lethality.
The level of IL-10 was suppressed in Gal-9-treated
CLP mice (Figure 4). Although IL-10 is an immuno-
suppressive cytokine, neutralization of IL-10 leads to
improved survival by restoring the downregulation of
the IL-18 receptor on NK cells and IFN-γ production in
septic mice [28,29].
Based on the present results, it is thus suggested that
it is important to increase IL-15 and IL-17 production
and to decrease IL-10 and HMGB1 production simul-
taneously to protect mice from CLP-induced lethality.
Furthermore, as we have previously proposed [41], Gal-9should be regarded as a homeostasis-maintaining factor
to keep an adequate immune response, not just as an
immunosuppressive factor or immunostimulatory factor.
Effects of Gal-9 on spleen T cells
As noted above, there are several types of T cells: CD4 T
cells (CD3+ CD4+), CD8 T cells (CD3+ CD8+), γδT cells
(CD3+ GL-3+) and NKT cells (CD3+ NK1.1+). Spleen
cells were obtained 24 hours after CLP. Flow cytometric
analysis was performed to clarify which types of T cells
are expanded by Gal-9 in CLP mice. The frequencies of
CD4 and CD8 T cells were not changed by Gal-9
(Figure 5A). We also assessed the frequency of Tim-3
expression on those T cells, because Tim-3 is a ligand of
Gal-9 [16]. Approximately 6% of CD4 T cells expressed
Tim-3 on their surface, and Gal-9 reduced the frequency
of Tim-3+ CD4 T cells, likely Th1 and Th17 cells
(Figure 5B), in agreement with our previous data that
Figure 5 Effects of galectin (Gal)-9 on subpopulations of spleen T cells. Spleen cells were obtained from PBS- or Gal-9-treated cecal ligation
and puncture (CLP) mice at 24 hours after a single intravenous injection. Flow cytometric analysis was performed to clarify which types of T cells
are expanded by Gal-9 in the spleens of CLP mice. (A) The frequencies of CD4 and CD8 T cells. Spleen cells were stained with CD3, CD4, CD8
and Tim-3, and fluorescence-activated cell sorting (FACS) analysis was performed; n = 5 for each group (NS, not significant). (B) The frequency of
Tim-3+ CD4 and CD8 T cells. Spleen cells were stained with CD3, CD4, CD8 and Tim-3, and FACS analysis was performed; n = 5 for each group
(NS, not significant; ***P <0.001). (C) The frequencies of natural killer T (NKT) cells and γδT cells. Spleen cells were stained with CD3, GL-3 and
NK1.1, and FACS analysis was performed; n = 5 for each group (NS, not significant; **P <0.001). (D) Expansion of Tim-3+ NKT cells but not γδT cells.
Spleen cells were stained with CD3, GL-3, NK1.1 and Tim-3, and FACS analysis was performed; n = 5 for each group (NS, not significant; ***P
<0.001). (E) Gal-9 treatment resulted in an increase of intracellular IL-17+ NKT cells. Spleen cells were stained with CD3, NK1.1 and intracellular
IL-17, and FACS analysis was performed; n = 5 for each group (*P <0.05).
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Th17 cells through a Gal-9/Tim-3 interaction [16-18]. In
contrast, Gal-9 weakly but not significantly increased
Tim-3+ CD8 T cells in the spleen of Gal-9-treated mice
(Figure 5B), suggesting that Gal-9 does not induce cell
death of Tim-3+ CD8 T cells, at least under these condi-
tions. Indeed, we have shown that Gal-9 potentiates
CD8 T cell-mediated antitumor immunity via Gal-9-
Tim-3 interactions between dendritic cells (DCs) and
CD8 T cells [41].
Moreover, Gal-9 increased the frequency of CD3+
NK1.1+ cells, most likely NKT cells (Figure 5C). Onethird of NK1.1+ NKT cells expressed Tim-3, and Gal-9
significantly increased the frequency of Tim-3-express-
ing NK1.1+ NKT cells (Figure 5D). In contrast, Gal-9 did
not increase the frequency of γδT cells (Figure 5C) or
the Tim-3 expression of those cells (Figure 5D). We
further found that Gal-9 treatment resulted in an
increase in the frequency of intracellular IL-17+ NKT
cells in the spleens of CLP mice (Figure 5E). These find-
ings suggest that Gal-9 does not induce cell death of
Tim-3-expressing NK1.1+ NKT cells, but enhances
activation of those cells to produce IL-17. It is not sur-
prising, because we had similar findings in our previous
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DCs to produce a small amount of TNF-α [42].
From the present experiments, NKT cells are proposed
to be one of the main cell-types responsible for the
Gal-9-induced prolongation of survival, by releasing
IL-17 in CLP mice. Regarding the role of NKT cells
in sepsis, there are competing opinions: one is that
NKT cells are involved in harmful outcomes in sepsis
as reviewed by Leung and Harris [43], and another is
that those cells exhibit a protective function in sepsis
[44,45]. Thus, it becomes important to explain such a
discrepancy. NKT cells are broadly categorized into at
least two groups: Type I NKT cells and Type II NKT
cells [46]. Furthermore, immune response in sepsis
consists of an initial hyper-reactive phase and a latent
phase. The initial hyper-reactive phase is characterized byFigure 6 Effects of galectin (Gal)-9 on splenic macrophages and dend
cecal ligation and puncture (CLP) mice at 24 hours after a single intravenou
increased frequency of plasmacytoid (p)DC-like macrophages (F4/80+ PDC
n = 5 for each group (NS, not significant; *P <0.05). (B) High Tim-3 expressio
(NS, not significant; ***P <0.001). Blue line, pDC-like macrophages; orange line,
pDC-like macrophages in Gal-9-treated CLP mice; n = 5 for each group (NS, nthe large release of pro-inflammatory cytokines from mac-
rophages et cetera, and the latent anti-inflammatory or
immunosuppressed phase is characterized by hypotensive
shock, inability to clear the infection, increased suscepti-
bility to nosocomial infections, and possible multiple
organ failure and death [47]. Our previous and present ex-
periments suggest that Gal-9 decreases pro-inflammatory
cytokine levels at the initial hyper-reactive phase [24]. In
contrast, Gal-9 decreases HMGB1 but increases IL-10
and IL-17. Gal-9 also expands Tim-3+ NK1.1+ NKT
cells and IL-17+ NKT cells. Therefore, we cannot ex-
clude the possibility that Tim-3 expressing NK1.1+
NKT cells produce IL-17 to protect sepsis through
the Gal-9/Tim-3 pathway. Thus, the hypothesis may
be proposed that Gal-9 contributes to downregulate the
early inflammatory response during sepsis but also toritic cells (DCs). Spleen cells were obtained from PBS- or Gal-9 treated
s injection and stained with F4/80, PDCA-1, CD11c and Tim-3. (A) An
A-1+ CD11c+) but not cDCs (F4/80- PDCA-1- CD11c+) was observed;
n on pDC-like macrophages was observed; n = 5 for each group
cDCs; red line, PDCA-1+ CD11c- cells. (C) Increased Tim-3-expressing
ot significant; ***P <0.001).
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studies are required to clarified this.Effects of Gal-9 on spleen macrophages and DCs
Because innate immune cells such as macrophages and
DCs may play a critical role in prolonging the survival of
septic mice by activating/regulating T cells [7,48,49], we
performed the experiments to clarify whether Gal-9 has
an effect on the frequency of macrophages or DCs.
Gal-9 markedly increased the frequency of plasmacy-
toid (p)DC-like macrophages (F4/80+ PDCA-1+ CD11c+),
although Gal-9 failed to increase the frequency of cDCs
(F4/80- PDCA-1- CD11c+) (Figure 6A).
Next, we assessed the Tim-3 expression on macro-
phages and DCs in the spleens of CLP mice. Intri-
guingly, half of the pDC-like macrophages expressed
Tim-3, although cDCs did not significantly express this
molecule (Figure 6B). Moreover, we compared the Tim-3
expression on splenic macrophages and DCs between the
Gal-9- and PBS-treated CLP mice. Gal-9 significantly
increased the frequency of Tim-3-expressing pDC-like
macrophages (Figure 6C). In contrast, the frequency of
Tim-3+ cDCs was low (Figure 6B), and Gal-9 failed to in-
crease the frequency of Tim-3-expressing cDCs in CLP
mice (Figure 6C). HMGB1 is a macrophage-derived late
proinflammatory cytokine, and TLR4 and CD14 are
required for the release of HMGB1 [50]. pDC-like macro-
phages suppress LPS-induced release of early proinflam-
matory cytokines from macrophages by suppressing TLR4
and CD14 expression on macrophages [21,22]. Thus, it
was suggested that immunosuppressive pDC-like mac-
rophages may mediate decreased release of early and
late proinflammatory cytokines from macrophages
that also, at least in part, may be involved in the pro-
longation of survival seen in these experiments. Of
course, further studies are required to ascertain
whether Tim-3+ NKT cells and pDC-like macrophages
are indeed involved in the survival prolongation indu-
ced by Gal-9.
Furthermore, the possibility that Gal-9 blocks the
PD-1/PD-L1 pathway cannot be excluded, as blocking
PD-1 improves survival in CLP mice [10-12]. There-
fore, further studies are required to clarify whether
Gal-9 affects PD-1 and PD-L1 expression on ma-
crophages and T cells and whether Gal-9 blocks the
PD-1/PD-L1 pathway.Conclusions
Gal-9 exhibits therapeutic effects on CLP-induced
polymicrobial sepsis, potentially by expanding NKT
cells and pDC-like macrophages, and by modulating
the production of early and late pro-inflammatory
cytokines.Key messages
 Delayed Gal-9 treatment prolongs the survival of
polymicrobial sepsis in mice induced by CLP.
 Gal-9 decreases TNFα, IL-6, IL-10 and HMGB1
levels but increases IL-15 and IL-17 levels.
 Gal-9 expands NKT cells and pDC-like
macrophages, although it decreases the frequency
of Tim-3+ CD4 T cells.
 Many NKT cells and pDC-like macrophages
express Tim-3, and Gal-9 increases the frequency
of Tim-3+ NKT cell and pDC-like macrophages.
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